Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study of dolutegravir + lamivudine fixed-dose combination vs tenofovir alafenamide–based regimen in virologically suppressed adults with HIV-1
jRCT2080223876Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of dolutegravir + lamivudine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Virologic failure at Week 48. Started Apr 2018; status: completed.
02
Drugs
dolutegravir + lamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2080223876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223876.